Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Maruho Files NDA for Japan’s First Infantile Hemangioma Treatment
September 28, 2015
- MEDINET Partners with Univ. of Tokyo in Joint Research for iPS Immuno-Cell Therapy
September 28, 2015
- Nihon Generic to Build New Factory with 10 Billion-Tablet Capacity
September 25, 2015
- MTPC, MedImmune Hook Up on Antibody Drug Conjugates
September 25, 2015
- NICE Recommends New Lixiana Indication for Health Coverage: Daiichi Sankyo
September 25, 2015
- Taiho Gets FDA Nod for Lonsurf, Its First Approval in US
September 25, 2015
- Terumo Aims at Annual Sales of 1-2 Billion Yen for HeartSheet within 5-10 Years
September 25, 2015
- Achieving New Share Target for Generics Will Be “Quite Difficult”: Hengrui Japan President
September 25, 2015
- Japan Approves JCR Pharma’s Cell-Based Acute GVHD Treatment
September 24, 2015
- Japan Grants 1st Conditional Approval to Terumo’s HeartSheet
September 24, 2015
- Novartis Files Afinitor for GI and Lung Neuroendocrine Tumors in Japan
September 24, 2015
- Amgen Gets Rights to MTPC’s Dyslipidemia Drug after Dezima Acquisition
September 18, 2015
- Chugai Seeks Cervical Cancer Indication for Avastin
September 18, 2015
- Opdivo Gets Breakthrough Therapy Designation for RCC
September 18, 2015
- 1 in 4 Elderly Japanese on 5 or More Prescribed Meds: Pharmacy Survey
September 17, 2015
- Eli Lilly’s Once-Weekly GLP-1 Hits Japan Market
September 17, 2015
- RaQualia Won’t Rule Out Control by Another Firm, Eyes Black Ink in 2018-2019: CEO
September 16, 2015
- Yervoy Will Be First Choice for BRAF-Negative Malignant Melanoma: Skin Cancer Specialist
September 16, 2015
- Daiichi Sankyo Licenses Thrombus Dissolving Agent from US Firm
September 16, 2015
- MTPC Calls Off Japan PIII Program for Alzheimer’s Treatment
September 16, 2015
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…